Are you Dr. Emanuel?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 68 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
10001 Lile Dr
Little Rock, AR 72205Phone+1 501-552-6100Fax+1 501-552-6199
Summary
- Dr. Peter Emanuel, MD is an oncologist in Little Rock, Arkansas. He is currently licensed to practice medicine in Arkansas and Alabama. He is affiliated with CHI St. Vincent Infirmary and is a Professor of Medicine at University Ark.
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991- University of Alabama Medical CenterResidency, Internal Medicine, 1985 - 1988
University of Wisconsin School of Medicine & Public HealthClass of 1985
Certifications & Licensure
AR State Medical License 2007 - 2026
AL State Medical License 1986 - 2024- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
Clinical Trials
- The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia Start of enrollment: 2009 Nov 01
Publications & Presentations
PubMed
- 206 citationsThe genomic landscape of juvenile myelomonocytic leukemia.Elliot Stieglitz, Amaro Taylor-Weiner, Tiffany Y. Chang, Laura C. Gelston, Yong Dong Wang
Nature Genetics. 2015-11-01 - 129 citationsA randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Jerald P. Radich, Kenneth J. Kopecky, Frederick R. Appelbaum, Suzanne Kamel-Reid, Wendy Stock
Blood. 2012-11-08 - 47 citationsImatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed ...Michael W. Deininger, Kenneth J. Kopecky, Jerald P. Radich, Suzanne Kamel-Reid, Wendy Stock
British Journal of Haematology. 2014-01-01
Press Mentions
Michael Birrer to Lead Winthrop P. Rockefeller Cancer InstituteSeptember 13th, 2019- Brad Baltz Joins CHI St. Vincent Cancer Care PracticeApril 4th, 2019
Ruxolitinib plus Azacitidine Improves Survival, Bone Marrow Fibrosis in MyelofibrosisNovember 13th, 2018- Join now to see all
Grant Support
- Construction Completion Of The Cancer Institute'S Shelled Space On Floors 9 And 1National Center For Research Resources2010
- Xray CrystallographyNational Cancer Institute2005–2009
- Transgenic AnimalNational Cancer Institute2005–2009
- Tissue ProcurementNational Cancer Institute2005–2009
- Small Animal ImagingNational Cancer Institute2005–2009
- Senior LeadershipNational Cancer Institute2005–2009
- Recruitment And RetentionNational Cancer Institute2005–2009
- Radiolabeling/DosimetryNational Cancer Institute2005–2009
- Protocol Specific Research SupportNational Cancer Institute2005–2009
- Protocol Review And MonitoringNational Cancer Institute2005–2009
- Planning &EvaluationNational Cancer Institute2005–2009
- Molecular NMRNational Cancer Institute2005–2009
- Molecular Biology /Recombinant ProteinNational Cancer Institute2005–2009
- Media PreparationNational Cancer Institute2005–2009
- Mass Spectroscopy/ProteomicsNational Cancer Institute2005–2009
- Major Program LeadersNational Cancer Institute2005–2009
- High Resolution MicroscopyNational Cancer Institute2005–2009
- Gene ExpressionNational Cancer Institute2005–2009
- DNA SequencingNational Cancer Institute2005–2009
- Developmental FundsNational Cancer Institute2005–2009
- Data And Safety MonitoringNational Cancer Institute2005–2009
- Clinical Protocol And Data ManagementNational Cancer Institute2005–2009
- Biostatistics/BioinformaticsNational Cancer Institute2005–2009
- Pathogenetic Alterations In Gene Specific RNA Translat*National Heart, Lung, And Blood Institute2007–2008
- North American Juvenile Myelomonocytic Leukemia ProjectNational Cancer Institute2007
- Pathogenetic Alterations In Gene Specific RNA Translat*National Heart, Lung, And Blood Institute2005–2007
- North American Juvenile Myelomonocytic Leukemia ProjectNational Cancer Institute2003–2007
- AdministrationNational Cancer Institute2005
- Comprehensive Cancer Center Core Support GrantNational Cancer Institute2004–2005
- Hematology Research Training ProgramNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2004
- Leukemia Therapy Based On Abnormal Signal TransductionNational Cancer Institute1999–2003
- Mechanisms Of Retinoic Acid On Leukemic ProliferationNational Cancer Institute1993–1996
- Hiv-Related Defective HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1989–1990
Professional Memberships
- Member
